Alexandria Real EstateARE

Alexandria reported a loss of $0.43 per share for the quarter, which was well below the $0.09 profit analysts expected. This loss was largely due to impairments, which are accounting charges taken when a company decides its assets, like lab buildings, are worth less than what is recorded on the books.

On a more positive note, revenue reached $0.64 billion, which was higher than the $0.46 billion expected. The company also highlighted its adjusted funds from operations, a key measure for real estate firms that shows the actual cash generated from its properties, at $1.73 per share. This suggests the underlying business of renting out specialized lab space remains functional even as the company cleans up its balance sheet.

See the full quarter, and how our tracked metrics did

Source: 8-K filing

Key highlights

• Rental income outlook steady: Management kept its 2026 forecast for funds from operations, a key profit measure for property owners, at a midpoint of $6.40 per share. This stability comes despite narrowing the expected range by 10 cents as the company navigates higher interest costs and tenant changes.
• Leasing volume picking up: The company signed leases for more than 1.0 million square feet this quarter, which is a 60% increase over the previous three months. Getting these deals done is vital for long term owners because 68% of the new activity came from existing tenants staying in the portfolio.
• Occupancy rates under pressure: Occupancy for the company's operating properties fell to 86.9%, down from 87.7% in the previous quarter. This drop was largely caused by several large tenants leaving their spaces in April 2026, creating a temporary gap in rental income.
• Smart construction cost cuts: By switching a project in Boston from laboratory space to technology use, the company expects to cut its construction budget by $80 million. Making these pivots helps protect cash while still delivering the space by the second quarter of 2027.
• Selling assets to pay debt: The company plans to sell $2.90 billion in properties and land this year to fund its building projects and pay down debt. So far, it has finished or has deals in progress for $1.33 billion of that goal, which is about 46% of the target.

Our take: This was a soft quarter as empty spaces from departing tenants weighed on the bottom line. While the company is successfully finding new tenants and cutting construction costs, the drop in occupancy to 86.9% shows the life science market remains challenging. It is a slow recovery, but the steady full year outlook keeps the long term case intact.